Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s Highly Qualified Director Nominees ...

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "We"), the largest stockholder of Keros Therapeutics ...

May 19, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of ...

AUSTIN - ADAR1 Capital Management, LLC, the major shareholder of Keros Therapeutics (NASDAQ:KROS), has urged the biotechnology firm to disclose the results of its strategic review before its ...

Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Keros ...

AUSTIN - ADAR1 Capital Management, LLC, the major shareholder of Keros Therapeutics (NASDAQ:KROS), has urged the biotechnology firm to disclose the results of its strategic review before its upcoming ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: KROS), a clinical-stage ...